CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Among the secondary outcomes, A1c reductions from baseline to week 26 were 0.7 with semaglutide vs 0.4 with placebo; increased percent time in range was 11.1% vs 2.3%; reductions in CGM mean ...

Researchers have found in phase IIIa REDEFINE 1 trial that Addition of investigational cagrilintide to GLP-1 agonist ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the GLP-1 receptor agonist weekly achieved the trial's primary composite outcome by week 26 compared with no patients in ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...